New drug duo aims to rally immune system against recurrent brain cancer
NCT ID NCT05345002
Summary
This study is testing whether combining two drugs—an oral vitamin A derivative (ATRA) and an immunotherapy (retifanlimab)—can help control recurrent brain tumors called IDH-mutant gliomas. The goal is to see if this combination is safe and can shrink tumors or stop their growth. The trial is for adults whose tumors have returned after prior chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.